Two peptides, two completely different strategies for the same problem. Retatrutide hits three receptors at once. Cagrilintide ignores the incretin pathway entirely and targets amylin instead. Both showed strong clinical results. Both sit in late-stage development. And yet they could not be more different in how they actually work inside your body.

This isn't a simple "which one is better" comparison. It's a question of mechanism, goals, and what you're actually trying to achieve. Let's break it down properly.

The receptor math

Retatrutide is a triple agonist. It hits GLP-1, GIP, and glucagon receptors simultaneously. Three distinct pathways working in parallel. GLP-1 handles appetite suppression through hypothalamic signaling and delayed gastric emptying. GIP improves lipid metabolism and insulin sensitivity. Glucagon drives energy expenditure up and accelerates hepatic fat oxidation. That third receptor is what separates retatrutide from everything else on the market, including tirzepatide, which only targets two.

Cagrilintide is a long-acting amylin analog. Amylin is co-secreted with insulin from pancreatic beta cells after meals. It works through AMY1, AMY2, and AMY3 receptors plus calcitonin receptors. Different brain regions, different signaling cascade. The satiety signal comes primarily through the area postrema, a brainstem structure sitting outside the blood-brain barrier. Natural amylin has a half-life of about 13 minutes. Cagrilintide extends that to roughly 160 hours, enabling once-weekly dosing.

So right away: retatrutide and cagrilintide are not competing variations on the same theme. They operate through fundamentally distinct hormonal pathways. This has real implications for who might benefit from each, and whether combining them could be worth exploring.

Clinical data: retatrutide

Jastreboff et al., published in NEJM, 2023. Phase II. 338 participants across multiple dose arms. Duration: 48 weeks.

The headline number: up to 24.2% body weight reduction at the highest dose (12mg). For context, that's roughly 58 pounds for someone starting at 240. In 48 weeks. That pace outstrips anything published for tirzepatide or semaglutide in comparable timeframes.

SURMOUNT-1 (tirzepatide's landmark trial) showed 22.5% at 72 weeks. Retatrutide got to 24% in two-thirds of that time. You can argue the populations differed, the trial designs weren't identical, Phase II versus Phase III, and you'd be right on all counts. But the direction is unmistakable. The glucagon component is adding real metabolic acceleration beyond what dual agonism can deliver.

Liver fat data was equally notable. Significant reductions across dose groups. Glucagon receptor activation directly promotes hepatic fat oxidation, so this was expected mechanistically, but seeing it quantified in a controlled trial matters. For anyone dealing with fatty liver, this is not a minor detail.

Lean mass preservation was another interesting signal. While the bulk of weight lost was fat mass, the ratio appeared somewhat more favorable than with GLP-1-only agents. The GIP component likely contributes here, as GIP has been associated with improved body composition outcomes in preclinical models. Phase III data will clarify whether this holds up statistically.

Phase III (TRIUMPH program) is ongoing, with multiple trials running globally. Full results are anticipated through 2025-2026. These will either confirm retatrutide's Phase II numbers at scale or reveal where the edge cases and limitations sit.

Clinical data: cagrilintide

Lau et al., Lancet, 2021. Phase II. 706 participants. 26 weeks.

Cagrilintide alone at the highest dose (4.5mg weekly) produced roughly 10.8% body weight loss. Not the kind of number that makes headlines in the age of 20%+ results from triple agonists. But context matters here. This was monotherapy, only 26 weeks, and using a pathway that had never been tested at this duration before.

What stood out was the dose-response curve. Cagrilintide showed a clean, linear dose-response relationship, meaning higher doses consistently produced more weight loss without the kind of plateau effect you sometimes see with GLP-1 agents. The 4.5mg dose was the highest tested, but the curve suggested further benefit at higher doses was plausible. This motivated the combination approach.

The more interesting story is CagriSema, Novo Nordisk's combination of cagrilintide with semaglutide 2.4mg. Phase II data showed approximately 15.6% body weight loss at 32 weeks. Phase III (REDEFINE program) expanded this further, with recent results suggesting weight loss in the range of 22-25% at 68 weeks. The amylin and GLP-1 pathways appear to be genuinely additive, not redundant.

Novo Nordisk filed for regulatory approval for CagriSema in 2025. If approved, it would be the first combined amylin-GLP-1 therapy on the pharmaceutical market. That alone makes cagrilintide worth understanding, because it represents a mechanistic pillar that the entire next generation of weight loss therapies may build on.

Mechanism differences that actually matter

Here's where it gets practical.

Energy expenditure: Retatrutide's glucagon component increases resting metabolic rate. Your body burns more calories at baseline. Cagrilintide does not have this effect. Amylin slows gastric emptying and reduces appetite, but it doesn't upregulate thermogenesis. If your primary concern is a stalled metabolism after prolonged dieting, this distinction carries weight.

Liver fat: Glucagon receptor activation drives hepatic fat breakdown directly. Retatrutide has demonstrated meaningful liver fat reductions in its Phase II data. Cagrilintide doesn't target this pathway. For research subjects with non-alcoholic fatty liver disease or elevated hepatic lipids, retatrutide has a clear mechanistic edge.

Appetite suppression quality: Both suppress appetite, but through different circuits. GLP-1 works primarily through the hypothalamus. Amylin works through the area postrema and the hindbrain. Some people respond strongly to one pathway and less to the other. If you've tried GLP-1 agonists and found the appetite suppression wearing off after a few months, cagrilintide's distinct mechanism might re-engage satiety signaling where incretin-based peptides stalled.

GI tolerance: Nausea from GLP-1 agonists is the number one complaint. Retatrutide includes GLP-1 activation, so yes, GI side effects track similarly to tirzepatide during dose escalation. Cagrilintide's side effect profile in its Phase II was milder on the GI front. Nausea occurred, but at lower rates and severity compared to GLP-1 agents. For people who struggled with nausea on semaglutide or tirzepatide, amylin agonism might be more tolerable.

Heart rate: Retatrutide's glucagon component was associated with modest heart rate increases (5-10 bpm) in some participants. Cagrilintide did not show this effect. If cardiovascular sensitivity is a concern, this is worth noting.

Blood glucose regulation: Both peptides have favorable effects on glycemic control, but through different mechanisms. Retatrutide's GLP-1 and GIP activity directly enhances insulin secretion and glucose disposal. Glucagon would normally raise glucose, but this is counterbalanced by the other two pathways. Cagrilintide suppresses post-meal glucagon secretion from alpha cells, which helps flatten glucose spikes after eating. For people with prediabetic glucose levels, either peptide offers a secondary benefit beyond weight loss.

Who is each one for?

If you're looking for maximum weight loss velocity, if you have liver fat concerns, if your metabolism feels genuinely suppressed after years of dieting, and if you tolerate GLP-1 class side effects reasonably well, [[Retatrutide|11]] is the more aggressive option. The triple receptor approach delivers the broadest metabolic impact available in a single peptide right now. The [[Retatrutide Pen|38]] makes the practicality even simpler: pre-filled, no reconstitution, just dial and inject.

If you've hit a plateau on GLP-1 agonists. If nausea has been a deal-breaker for you on semaglutide or tirzepatide. If you want to target appetite through a completely different receptor pathway. Or if you're researching combination approaches (amylin + incretin), [[Cagrilintide|12]] is the one to explore. It's a different tool for a different bottleneck.

There's also the stacking angle. Since retatrutide and cagrilintide work through non-overlapping receptor systems, the theoretical case for combining them exists. Novo Nordisk proved the concept with CagriSema (amylin + GLP-1). A triple agonist plus an amylin analog would cover four receptor families. No published trial has tested this combination directly, but the mechanistic logic is sound. This is strictly a research consideration, not a recommendation.

Dosing and practical notes

[[Retatrutide|11]] follows the standard escalation approach. Start at a lower dose, increase monthly over the first 8-12 weeks, then maintain. This is non-negotiable if you want to avoid unnecessary GI distress. Available in 10mg, 30mg, and 60mg vials for reconstitution. The [[Retatrutide Pen|38]] comes pre-filled in 30mg and 60mg for people who prefer convenience.

Cagrilintide dosing in the Phase II trial ramped from 0.3mg to 4.5mg weekly over 16 weeks. Injection once a week, subcutaneous. [[Cagrilintide|12]] is supplied as a lyophilized powder for reconstitution with bacteriostatic water.

Both peptides require cold storage (2-8°C) before reconstitution and should be kept refrigerated after mixing. Standard peptide handling rules apply. Use ins...